Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.425 SEK | +1.44% |
|
-5.34% | -4.59% |
Jul. 01 | SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon | CI |
May. 31 | SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-4.59% | 33.04M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- SYNACT Stock
- News SynAct Pharma AB
- SynAct Pharma AB Approves Election of Marina Bozilenko as a New Board Member